Login
- Dokumenttyp:
- Journal Article; Journal Article
- Autor(en):
- Jaramillo, S; Benner, A; Krauter, J; Martin, H; Kindler, T; Bentz, M; Salih, H R; Held, G; Köhne, C-H; Götze, K; Lübbert, M; Kündgen, A; Brossart, P; Wattad, M; Salwender, H; Hertenstein, B; Nachbaur, D; Wulf, G; Horst, H-A; Kirchen, H; Fiedler, W; Raghavachar, A; Russ, G; Kremers, S; Koller, E; Runde, V; Heil, G; Weber, D; Göhring, G; Döhner, K; Ganser, A; Döhner, H; Schlenk, R F
- Titel:
- Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia.
- Abstract:
- The aim of this cohort study was to compare a condensed schedule of consolidation therapy with high-dose cytarabine on days 1, 2 and 3 (HDAC-123) with the HDAC schedule given on days 1, 3 and 5 (HDAC-135) as well as to evaluate the prophylactic use of pegfilgrastim after chemotherapy in younger patients with acute myeloid leukemia in first complete remission. One hundred and seventy-six patients were treated with HDAC-135 and 392 patients with HDAC-123 with prophylactic pegfilgrastim at days 10 and 8, respectively, in the AMLSG 07-04 and the German AML Intergroup protocol. Time from start to chemotherapy until hematologic recovery with white blood cells >1.0 G/l and neutrophils >0.5 G/l was in median 4 days shorter in patients receiving HDAC-123 compared with HDAC-135 (P<0.0001, each), and further reduced by 2 days (P<0.0001) by pegfilgrastim. Rates of infections were reduced by HDAC-123 (P<0.0001) and pegfilgrastim (P=0.002). Days in hospital and platelet transfusions were significantly reduced by HDAC-123 compared with HDAC-135. Survival was neither affected by HDAC-123 versus HDAC-135 nor by pegfilgrastim. In conclusion, consolidation therapy with HDAC-123 leads to faster hematologic recovery and less infections, platelet transfusions as well as days in hospital without affecting survival.
- Zeitschriftentitel:
- Blood Cancer J
- Jahr:
- 2017
- Band / Volume:
- 7
- Heft / Issue:
- 5
- Seitenangaben Beitrag:
- e564
- Sprache:
- eng
- Volltext / DOI:
- doi:10.1038/bcj.2017.45
- PubMed:
- http://view.ncbi.nlm.nih.gov/pubmed/28548643
- Print-ISSN:
- 2044-5385
- TUM Einrichtung:
- III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
BibTeX
Vorkommen: